Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-16
2006-05-16
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S114000, C544S127000, C544S180000, C544S331000, C544S336000, C544S362000, C514S233800, C514S241000, C514S253030, C514S275000
Reexamination Certificate
active
07045528
ABSTRACT:
The invention relates to compounds represented by the formula Iand to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11and R14, R15, R16, and R17are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
REFERENCES:
patent: 5587458 (1996-12-01), King et al.
patent: 5747498 (1998-05-01), Schnur
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5861510 (1999-01-01), Piscopio et al.
patent: 5863949 (1999-01-01), Robinson et al.
patent: 5877305 (1999-03-01), Huston et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 6071935 (2000-06-01), Lyssikatos
patent: 6225318 (2001-05-01), Sobolov-Jaynes et al.
patent: 6492383 (2002-12-01), Munchhof et al.
patent: 6502129 (2002-12-01), Stewart et al.
patent: 0606046 (1993-12-01), None
patent: 0 780 386 (2002-10-01), None
patent: 0 931 788 (2002-11-01), None
patent: WO 90/05719 (1990-05-01), None
patent: WO 95/19970 (1995-07-01), None
patent: WO 95/21613 (1995-08-01), None
patent: WO 95/23141 (1995-08-01), None
patent: WO 96/14843 (1996-05-01), None
patent: WO 96/27583 (1996-09-01), None
patent: WO 96/30347 (1996-10-01), None
patent: WO 96/33172 (1996-10-01), None
patent: WO 96/40142 (1996-12-01), None
patent: WO 97/13760 (1997-04-01), None
patent: WO 97/13771 (1997-04-01), None
patent: WO 97/22596 (1997-06-01), None
patent: WO 97/32856 (1997-09-01), None
patent: WO 97/34876 (1997-09-01), None
patent: WO 97/49688 (1997-12-01), None
patent: WO 98/01113 (1998-01-01), None
patent: WO 98/02434 (1998-01-01), None
patent: WO 98/02437 (1998-01-01), None
patent: WO98/02438 (1998-01-01), None
patent: WO 98/03516 (1998-01-01), None
patent: WO 98/07697 (1998-02-01), None
patent: WO 98/14451 (1998-04-01), None
patent: WO 98/23613 (1998-06-01), None
patent: WO 98/30566 (1998-07-01), None
patent: WO 98/33768 (1998-08-01), None
patent: WO 98/34915 (1998-08-01), None
patent: WO 98/34918 (1998-08-01), None
patent: WO 98/50356 (1998-11-01), None
patent: WO 98/54093 (1998-12-01), None
patent: WO 99/00797 (1999-01-01), None
patent: WO 99/10349 (1999-03-01), None
patent: WO 99/16755 (1999-04-01), None
patent: WO 99/21845 (1999-05-01), None
patent: WO 99/24440 (1999-05-01), None
patent: WO 99/29667 (1999-06-01), None
patent: WO 99/35132 (1999-07-01), None
patent: WO 99/35146 (1999-07-01), None
patent: WO 99/52889 (1999-10-01), None
patent: WO 99/52910 (1999-10-01), None
patent: WO 99/61422 (1999-12-01), None
patent: WO 00/38665 (2000-07-01), None
patent: WO 01/94353 (2001-12-01), None
patent: WO 03/000194 (2003-01-01), None
patent: WO 03/074529 (2003-09-01), None
Bagshawe, et. al., “Antibody-Directed Enzyme Therapy: A Review,”Drug Development and Research,1995, 220-230, 34.
Bertolini, et. al., “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug,”Journal of Medicinal Chemistry,1997, 2011-2016, 40.
Bodor, et. al., “Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems,”Advances in Drug Res.,1984, 224-331, 13.
Bundgaard, et. al.,Design and Application of Prodrugs, Drug Design and Development, Harwood Academic Press, 1991.
Bundgaard, et. al.,Design of Prodrugs, Elsevier Press, 1985, New York.
Buttery, et. al., “Preparation of 2,3-Disubstituted Indoles from Indole-3-carboxylic Acids and Amides by Deprotonation,”Journal of Chem. Soc. Perkin Trans,1993, 1425-1431.
Pagano, Michele ed., Cell Cycle: Materials and Methods, 1995, Berlin, Germany.
Fleisher, et. al., , “Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs,”Advanced Drug Delivery Reviews1996, 115-130, vol. 19.
Green, T., et. al.,Protecting Groups in Chemical Synthesis (3rdEdition), 1999, John Wiley & Sons, New York.
Mohammadi., et. al., “Identification of Six N0vel Autophosphorylation Sites on Fibroblast Growth Factor Receptor 1 and Elucidation of Their Importance in Receptor Activation and Signal Transduction,”Molecular Cell and Biology,1996, 977-989, vol. 16, No. 3.
Parast, et. al., “Characterization and Kinetic Mechanism of Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR 2 TK), a Key Enzyme in Angiogenesis,”Biochemistry,1998, 16788-16801, 37.
Robinson, et. al., “Discovery of the Hemifumarate and (a-L-Alanylogy) methyl Ether as Prodrugs of an Antirheumatic Oxiindole: Prodrugs for the Enolic OH Group,”Journal of Medicinal Chemistry, 1996, 39, 1, 10-18.
Shan, et. al., , “Prodrug Strategies Based on Intramolecular Cyclization Reactions,”Journal of Pharmaceutical Science,1997, 765-767, vol. 86, No. 7.
Still, et. al., “Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution,”Journal of Organic Chemistry,1978, 2923-2925, vol. 43, No. 14.
Swain, et. al., “Novel 5-HT3Antagonists: Indol-3-ylspiro(azabicycloalkane-3,5' (4'H)-oxazoles),”Journal of Med. Chemistry,1992, 1019-1031, 35.
Collins Michael
Cripps Stephan
Deal Judith
He Mingying
Kania Robert Steven
Agouron Pharmaceuticals , Inc.
Aulakh Charanjit S.
Robinson Edward D.
Zielinski Bryan C.
LandOfFree
Benzofused heterozryl amide derivatives of thienopyridines... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzofused heterozryl amide derivatives of thienopyridines..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzofused heterozryl amide derivatives of thienopyridines... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3642785